Capsida and AbbVie’s Gene Therapy Collaboration Yields Promising Results for Eye Diseases

Expanded Collaboration:
Capsida Biotherapeutics and AbbVie have expanded their strategic collaboration to develop targeted genetic medicines for eye diseases with high unmet need12.

Financial Terms:
Capsida will receive $70 million upfront and is eligible for up to $595 million in option fees and research and development milestones, with potential for further commercial milestones and royalties24.

Roles and Responsibilities:
Capsida will lead capsid discovery efforts and early clinical manufacturing, while AbbVie will lead therapeutic cargo approaches and be responsible for development and commercialization12.

Platform and Expertise:
The collaboration combines AbbVie's extensive capabilities in eye disease drug development and commercialization with Capsida's novel AAV engineering platform and manufacturing capabilities24.

Therapeutic Focus:
The partnership aims to develop three targeted genetic medicines for eye diseases, marking Capsida's entry into ophthalmology24.

Previous Partnerships:
This collaboration builds upon a 2021 neurodegenerative disease partnership between AbbVie and Capsida, and follows a recent deal with Eli Lilly for neurodegenerative conditions4.

Sources:

1. https://www.biopharminternational.com/view/abbvie-and-capsida-strike-674-million-gene-therapy-development-deal

2. https://www.prnewswire.com/news-releases/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medicines-for-eye-diseases-with-high-unmet-need-301753510.html

4. https://www.fiercebiotech.com/biotech/capsida-reels-another-big-pharma-deal-time-diving-eye-disease-abbvie